I’m actually at a loss to understand why that 3rd patient (with Usher’s syndrome) was enrolled. The whole focus of PYC’s treatment at this stage is on monogenic disease. The 3rd patient has mutations in 2 genes, not one. So the (monogenic) treatment was bound to have little to no effect. Surely they could have found a 3rd patient with just the single mutation?!?
PYC Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)